TXMD News and Press, TherapeuticsMD Inc. From 08/17/22

TherapeuticsMD's birth control ring saw year-over-year growth of almost 100% in Q2. Although costs came down significantly, TXMD continued to report an operating loss. Management believes a resolution to its recent inventory headwinds along with government support will drive incre...

Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q2 2022 Earnings Call Aug 15, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript

Viridian Therapeutics ( VRDN ) surged nearly 60% in Monday's midday trading, bolstered by the release of strong clinical data related to a potential treatment of Thyroid Eye Disease. In other news, TherapeuticsMD ( TXMD ) and SNDL ( SNDL ) jumped on strong quarterly reports....

Therapeutics MD ( NASDAQ: TXMD ) is trading 22% higher after the company posted a 24%rise in revenue, helped by strong sales of Annovera. The company posted Revenue of $28.6M, while Q2 GAAP EPS was $12.39. Vaginal ring Annovera net product revenue rose...

Gainers: Viridian Therapeutics VRDN +45% . TherapeuticsMD TXMD +21% . Unity Biotechnology UBX +21% . Brainstorm Cell Therapeutics BCLI +12% . Genprex GNPX +10% . Losers: IDEAYA Biosciences IDYA -33% . Apexigen ( APGN ) -15%...

TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Conference Call August 15, 2022 8:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Chief Commercial Officer Conference Call Participants Dou...

The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: TherapeuticsMD, Inc. 2022 Q2 - Results - Earnings Call Presentation

Therapeutics MD press release ( NASDAQ: TXMD ): Q2 GAAP EPS of $12.39. Revenue of $28.6M (+24.3% Y/Y). As of June 30, 2022, the Company’s cash on hand totaled $26.3 million, compared with $65.1 million as of December 31, 2021. For further details see: ...

- Quarterly total net revenue of $28.6 million - - ANNOVERA ® TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innov...

Therapeutics MD ( NASDAQ: TXMD ) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$3.04 (-2663.6% Y/Y) and the consensus Revenue Estimate is $23.2M (+0.9% Y/Y). Over the last 1 year, TXMD has beat...